---
title: "Evidence: Lipoprotein(a) concentration"
description: "Higher lipoprotein(a) levels are modestly and independently associated with an increased risk of coronary heart disease and stroke, but not with…"
url: "https://magellanlongevity.com/study/s141.md"
canonical: "https://magellanlongevity.com/study/s141.html"
html: "https://magellanlongevity.com/study/s141.html"
type: "study"
study_key: "s141"
journal: "JAMA"
year: 2009
pmid: "19622820"
doi: "10.1001/jama.2009.1063"
citations: 1
updated: 2026-09-02
author: "Gabriel Radu, DO"
author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765."
publisher: "Magellan Longevity"
content_format: "markdown"
---

# Evidence: Lipoprotein(a) concentration

[Home](https://magellanlongevity.com/) › [Research map](https://magellanlongevity.com/longevity-research-map.html) › Evidence: Lipoprotein(a) concentration

**HTML version:** https://magellanlongevity.com/study/s141.html · **In the Magellan app:** https://magellanlongevity.com/#/study/s141

## Citation

| Field | Value |
| --- | --- |
| Journal | JAMA |
| Year | 2009 |
| PMID | [19622820](https://pubmed.ncbi.nlm.nih.gov/19622820/) |
| DOI | [10.1001/jama.2009.1063](https://doi.org/10.1001/jama.2009.1063) |
| Study key | s141 |

## Takeaway

Higher lipoprotein(a) levels are modestly and independently associated with an increased risk of coronary heart disease and stroke, but not with nonvascular deaths.

## The question

What is the relationship between lipoprotein(a) (Lp[a]) concentration and the risk of major vascular and nonvascular outcomes?

## Hypothesis

Circulating concentration of lipoprotein(a) (Lp[a]) may be associated with an increased risk of coronary heart disease (CHD) and stroke.

## Methods

This study identified 36 long-term prospective studies published between January 1970 and March 2009 that recorded Lp(a) concentration and subsequent major vascular morbidity and/or cause-specific mortality. Individual records for 126,634 participants were analyzed, excluding those with preexisting CHD or stroke at baseline. Within-study regression analyses, adjusted for within-person variation, were combined using meta-analysis.

## Results

During 1.3 million person-years of follow-up, 22,076 first-ever fatal or nonfatal vascular disease outcomes or nonvascular deaths were recorded. Lp(a) concentration showed weak correlation with conventional vascular risk factors and was highly consistent within individuals over several years. The rates of CHD in the top and bottom thirds of baseline Lp(a) distributions were 5.6 and 4.4 per 1000 person-years, respectively. The risk ratio for CHD was 1.16 per 3.5-fold higher usual Lp(a) concentration (adjusted for age and sex) and 1.13 after further adjustment for other risk factors. The adjusted risk ratio for ischemic stroke was 1.10, while for nonvascular mortality, cancer deaths, and nonvascular deaths other than cancer, the risk ratios were 1.01, 1.00, and 1.00, respectively.

## Conclusion

Lp(a) concentration has continuous, independent, and modest associations with the risk of coronary heart disease and stroke, and these associations appear to be exclusive to vascular outcomes.

## Limitations

The abstract does not explicitly state limitations of the study.

## Verbatim from the abstract

> continuous, independent, and modest associations of Lp(a) concentration with risk of coronary heart disease and stroke

## CHD Rates by Lp(a) Concentration Thirds

| Measure | CHD Rate (per 1000 person-years) |
| --- | --- |
| Bottom Third Lp(a) | 4.4 |
| Top Third Lp(a) | 5.6 |

*Rates of coronary heart disease (CHD) per 1000 person-years in participants categorized by their baseline Lp(a) concentration thirds.*

## Where this study is used on Magellan

This paper is one of the citations behind the evidence grade on the pages below. Grades are assigned from the published research and are independent of affiliate commissions.

| Compound or device | Evidence grade | Graded pages |
| --- | --- | --- |
| Lp(a) Mail-In Test | Measurement tool | [Lp(a) Mail-In Test](https://magellanlongevity.com/p/141.md) |

## Reference

1. **Evidence: Lipoprotein(a) concentration**
   JAMA 2009 · [PMID 19622820](https://pubmed.ncbi.nlm.nih.gov/19622820/) · [DOI 10.1001/jama.2009.1063](https://doi.org/10.1001/jama.2009.1063)

   > continuous, independent, and modest associations of Lp(a) concentration with risk of coronary heart disease and stroke

## Structured data

```json
{"@context":"https://schema.org","@graph":[{"@type":"MedicalWebPage","@id":"https://magellanlongevity.com/study/s141.html#page","url":"https://magellanlongevity.com/study/s141.html","name":"Evidence: Lipoprotein(a) concentration","description":"Higher lipoprotein(a) levels are modestly and independently associated with an increased risk of coronary heart disease and stroke, but not with…","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/study/s141.md"},"dateModified":"2026-09-02"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Research map","item":"https://magellanlongevity.com/longevity-research-map.html"},{"@type":"ListItem","position":3,"name":"Evidence: Lipoprotein(a) concentration","item":"https://magellanlongevity.com/study/s141.html"}]},{"@type":"ScholarlyArticle","@id":"https://magellanlongevity.com/study/s141.html#study","name":"Evidence: Lipoprotein(a) concentration","headline":"Evidence: Lipoprotein(a) concentration","datePublished":"2009","isPartOf":{"@type":"Periodical","name":"JAMA"},"identifier":"PMID:19622820","url":"https://pubmed.ncbi.nlm.nih.gov/19622820/","sameAs":"https://doi.org/10.1001/jama.2009.1063","abstract":"Higher lipoprotein(a) levels are modestly and independently associated with an increased risk of coronary heart disease and stroke, but not with nonvascular deaths."}]}
```

## Related on Magellan Longevity

- [Lp(a) Mail-In Test](https://magellanlongevity.com/p/141.md) — product graded on this and related evidence
- [Lipoprotein(a) and Cardiovascular Disease](https://magellanlongevity.com/study/d33236085.md)
- [Elevated Lipoprotein(a) and Risk of Atrial Fibrillation](https://magellanlongevity.com/study/d35450575.md)
- [Longevity research map](https://magellanlongevity.com/longevity-research-map.html)
- [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md)

## Scope and disclosures

Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication.

Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases.

Reviewed for accuracy by a board-certified physician (DO).